Pharmacy in FR. Official registry identity, source coverage and the current valuation evidence status on one public company profile.
The latest filing has no usable positive EBITDA or the sector multiple is not available yet.
Create a free account to add verified turnover, normalised EBITDA, debt and one-offs for PHARMACIE DUBESSET-LEBARGY SELARL in a private workspace.
We keep this public page conservative, so weak filings never become a false price.The page can still show filed facts, but the automatic public range is blocked when those facts would make the multiple misleading.
PHARMACIE DUBESSET-LEBARGY SELARL, a pharmacy, is registered at an address in France. The company was founded in 2001, incorporated as a 5485.
PHARMACIE DUBESSET-LEBARGY SELARL is listed in French National Business Register (RNE/INPI) under registry number 435303193. The public employee band is 03, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 47.73 band file annual accounts with INPI.
Across the 2017-2024 window revenue has more than doubled, moving from €1,305,268 to €2,071,511.
The most recent annual filing covers 2024 (period end 2024-09-30).
The data on this page is a public, point-in-time view of PHARMACIE DUBESSET-LEBARGY SELARL's regulator-filed footprint, built to support sellability context and acquisition research without overstating the public valuation evidence.
PHARMACIE DUBESSET-LEBARGY SELARL's public data is not clean enough for an automated valuation curve yet. Owner or advisor data can add the missing turnover, normalised EBITDA and adjustments.
Express interest and ask Upswitch to discreetly sound out the owner. We review every request before making contact.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202430 Sept 2024 | €2,071,511 | - | €1,867,238 | €1,062,674 | - |
| 202330 Sept 2023 | €1,930,556 | - | €2,002,385 | €1,068,814 | - |
| 202230 Sept 2022 | €1,621,661 | - | €1,808,150 | €1,072,884 | - |
| 202130 Sept 2021 | €1,366,539 | - | €1,682,604 | €1,122,223 | - |
| 202030 Sept 2020 | €1,309,648 | - | €1,611,237 | €1,148,088 | - |
| 201930 Sept 2019 | €1,308,156 | - | €1,516,672 | €1,050,762 | - |
| 201830 Sept 2018 | €1,323,745 | - | €1,566,941 | €1,030,565 | - |
| 201730 Sept 2017 | €1,305,268 | - | €1,562,432 | €1,028,322 | - |
PHARMACIE DUBESSET-LEBARGY SELARL was founded in 2001 and is registered with French National Business Register (RNE/INPI), incorporated as a 5485.
PHARMACIE DUBESSET-LEBARGY SELARL is registered under NACE 47.73: NACE 47.73. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-09-30), publicly available via French National Business Register (RNE/INPI).
This page shows official or licensed public company facts and valuation-readiness context for PHARMACIE DUBESSET-LEBARGY SELARL; it does not show an automated public valuation range. The available facts may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
